Argus Research Maintains Buy on AstraZeneca, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst Jasper Hellweg maintains a Buy rating on AstraZeneca (NASDAQ:AZN) but lowers the price target from $85 to $80.
May 26, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Argus Research maintains a Buy rating on AstraZeneca (NASDAQ:AZN) but lowers the price target from $85 to $80.
The news of Argus Research maintaining a Buy rating on AstraZeneca is positive for the stock. However, the lowering of the price target from $85 to $80 may create some uncertainty among investors. The overall impact on the stock price in the short term is expected to be neutral as the positive and negative factors balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100